Biocon – A research center in Bangalore launches drug for Skin disease
Biocon – India’s leading biotechnology company has launched a new drug to treat a skin disease called psoriasis. This condition takes place when the immune system mistakes a normal skin cells as a pathogen.
“Psoriasis is a common disease which affects 3% of the world population and which 2% of population affects India approximately 1.2 billion people. The global psoriasis market size is estimated to cross $8 billion by 2016,” the company said in a statement here on Sunday.
“The drug is an outcome of our path-breaking research and will bring a paradigm shift in the management of skin disorder. The molecule has potential to treat multiple auto-immune diseases and make a difference to a larger patient population worldwide,” Biocon chairperson Kiran Mazumdar-Shaw said in the statement.
An infusion drug to treat psoriasis, Alzuma will be manufactured after regulatory clearances
Skin Disease – Psoriasis
“With a unique mechanism, the drug offers safety profile compared to other therapies, and has a long remission period with low opportunistic infection rate,” Shaw said.
The new drug also demonstrated pre-clinical and post-clinical evidence in treating other autoimmune diseases like rheumatoid arthritis, psoriatic arthritis and multiple sclerosis.
“We are committed to address the unmet need of patients suffering from psoriasis through the new drug, which has better safety and efficacy profile to patients with longer remission periods and lower infection rates,” said Biocon president (marketing) Rakesh Bamzai in the statement.